PriceTargets.com logo

Lyra Therapeutics - LYRA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.50
  • Forecasted Upside: 2,428.09%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.18 As of 11/20/2024 01:00 AM ET
▼ -0.02 (-10.10%)

This chart shows the closing price for LYRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lyra Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LYRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LYRA

Analyst Price Target is $4.50
▲ +2,428.09% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Lyra Therapeutics in the last 3 months. The average price target is $4.50, with a high forecast of $11.00 and a low forecast of $0.50. The average price target represents a 2,428.09% upside from the last price of $0.18.

This chart shows the closing price for LYRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Lyra Therapeutics. This rating has held steady since April 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/30/2024William BlairUpgradeHold
8/15/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
8/15/2024Cantor FitzgeraldReiterated RatingOverweight
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
5/7/2024HC WainwrightDowngradeBuy ➝ Neutral$12.00 ➝ $2.00
5/7/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$10.00 ➝ $0.50
5/7/2024Bank of AmericaDowngradeBuy ➝ Underperform
5/6/2024BTIG ResearchReiterated RatingBuy ➝ Neutral
5/6/2024William BlairDowngradeOutperform ➝ Market Perform
5/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
3/25/2024Bank of AmericaLower TargetBuy ➝ Buy$12.00 ➝ $11.00
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
10/6/2023BTIG ResearchReiterated RatingBuy$15.00
10/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00
9/12/2023Bank of AmericaBoost TargetBuy ➝ Buy$13.00 ➝ $15.00
8/31/2023HC WainwrightInitiated CoverageBuy$12.00
2/7/2023BTIG ResearchLower TargetBuy$24.00 ➝ $20.00
5/24/2022Cantor FitzgeraldInitiated CoverageOverweight$15.00
5/10/2022William BlairReiterated RatingOutperform
6/10/2021BTIG ResearchReiterated RatingBuy
5/19/2021BTIG ResearchReiterated RatingBuy
12/7/2020Bank of AmericaBoost Target$19.00 ➝ $26.00
5/26/2020William BlairInitiated CoverageOutperform
5/26/2020BTIG ResearchInitiated CoverageBuy$28.00
5/26/2020Bank of AmericaInitiated CoverageBuy$21.00
5/26/2020Jefferies Financial GroupInitiated CoverageBuy$24.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Lyra Therapeutics logo
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $0.18
Low: $0.17
High: $0.20

50 Day Range

MA: $0.25
Low: $0.17
High: $0.28

52 Week Range

Now: $0.18
Low: $0.16
High: $6.79

Volume

6,652,244 shs

Average Volume

1,720,522 shs

Market Capitalization

$11.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lyra Therapeutics?

The following Wall Street analysts have issued stock ratings on Lyra Therapeutics in the last twelve months: Bank of America Co., BTIG Research, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., and William Blair.
View the latest analyst ratings for LYRA.

What is the current price target for Lyra Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Lyra Therapeutics in the last year. Their average twelve-month price target is $4.50, suggesting a possible upside of 2,428.1%. Bank of America Co. has the highest price target set, predicting LYRA will reach $11.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $0.50 for Lyra Therapeutics in the next year.
View the latest price targets for LYRA.

What is the current consensus analyst rating for Lyra Therapeutics?

Lyra Therapeutics currently has 1 sell rating, 4 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LYRA, but not buy more shares or sell existing shares.
View the latest ratings for LYRA.

What other companies compete with Lyra Therapeutics?

Other companies that are similar to Lyra Therapeutics include Envoy Medical, iCAD, Outset Medical, Beyond Air and Precision Optics. Learn More about companies similar to Lyra Therapeutics.

How do I contact Lyra Therapeutics' investor relations team?

Lyra Therapeutics' physical mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The company's listed phone number is 617-393-4600 and its investor relations email address is [email protected]. The official website for Lyra Therapeutics is www.lyratherapeutics.com. Learn More about contacing Lyra Therapeutics investor relations.